Revvity opened lower at $164.21, compared with its previous close of $165.78. In the last trading session, the stock traded between $155.85 and $164.21. It showed a downward intraday trend.
An investment of $100 made 4 years ago in Revvity is now worth
$ 136.86
giving a profit of
$ 36.86 (36.86%)
Note: Past profits do not guarantee future returns.
Rating from 12 Analysts
Today's Change
$-9.47 (-5.71%)
Day High
$164.21
Day Low
$155.85
Day Open
$164.21
Prev Close
$165.78
Volume
10,78,316
1W Return
-0.67%
1M Return
2.30%
3M Return
37.96%
6M Return
90.02%
1Y Return
64.02%
Market Cap ($ Mn)
17,442
PE Ratio
61.63
PB Ratio
1.99
PEG Ratio
16.83
ROE
3.20%
ROCE
2.89%
EPS (TTM)
$0.46
1 Week
-0.67%
1 Month
2.30%
3 Months
37.96%
6 Months
90.02%
9 Months
44.08%
Revvity to release Q3 2026 earnings on November 3
Revvity will release Q3 2026 results on November 3, 2026. Conference call scheduled for 7:30 am ET same day. CEO Prahlad Singh and CFO Max Krakowiak will host the call. Company reported $2.9 billion revenue in 2025.
28 days agoRevvity Q2FY26 Results: Organic growth hits 3%, adjusted EPS $1.41
Revvity reported Q2FY26 pro forma organic growth of 3% and adjusted EPS of $1.41, exceeding guidance. Diagnostics segment grew 11% organically to $352 million, driven by reproductive health and newborn screening. Life Sciences revenue declined 3% organically to $359 million due to a 20% drop in Signals software revenue. Full-year adjusted EPS guidance raised to $5.30-$5.40; organic growth outlook increased to 4-5%. Free cash flow reached $184 million with a 117% conversion rate of adjusted net income.
1mo agoRevvity stock delivers 14.61% annualized return over 15 years
Revvity delivered a 14.61% average annual return over the past 15 years. The stock outperformed the market by 1.11% on an annualized basis. Current market capitalization stands at $16.24 billion. A $1,000 investment from 15 years ago is now worth $7,469.50.
1mo agoRevvity acquires Human Cell Design to expand metabolic disease research portfolio
Revvity to acquire Human Cell Design, adding human pancreatic beta cell models to its Life Sciences portfolio. Transaction expected to close in Q4 2026, subject to regulatory approvals and customary conditions. Deal targets exposure to GLP-1 and metabolic disease therapies via HCD's EndoC-βH5 cell models. Integration leverages Revvity's HTRF, AlphaLISA, and pHSense technologies for enhanced drug discovery.
1mo agoRevvity Q2 Results: Organic growth hits 3%, EPS guide raised
Revvity’s Q2 2026 results show $711 million in revenue with 3% organic growth, driven by an 11% rise in Diagnostics. The company raised full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40. A definitive agreement to divest the China immunodiagnostics business was signed, with completion expected by end-2027.
2mo agoRevvity declares $0.07 quarterly dividend for shareholders
Revvity, Inc. declared a $0.07 per share quarterly dividend, payable on November 13, 2026, to shareholders of record on October 23, 2026. The health science solutions provider, which reported $2.9 billion in revenue for 2025, continues to reward investors through consistent capital returns.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $709.18 | +0.71% | $2,62,217.18M | 33.49 | |
| $236.98 | +1.24% | $1,66,722.78M | 38.52 | |
| $436.00 | +2.73% | $62,846.78M | - | |
| $181.15 | -0.18% | $51,071.44M | 30.34 | |
| $480.07 | +0.67% | $47,165.92M | 104.98 | |
| $575.98 | +2.32% | $45,376.28M | 39.00 | |
| $275.06 | -1.43% | $45,329.89M | 32.52 | |
| $290.06 | +0.44% | $43,799.06M | 40.22 | |
| $1,718.61 | +1.19% | $34,435.79M | 31.52 | |
| $368.16 | +2.20% | $29,857.78M | 27.72 | |
| $252.92 | +2.97% | $27,826.01M | 25.77 | |
| $185.31 | +1.49% | $24,867.86M | - |
An investment of $100 made 4 years ago in Revvity is now worth
$ 136.86
giving a profit of
$ 36.86 (36.86%)
Note: Past profits do not guarantee future returns.
